Population Pharmacokinetics of CCI‐779: Correlations to Safety and Pharmacogenomic Responses in Patients with Advanced Renal Cancer

Our objective was to estimate the pharmacokinetic parameters of CCI‐779 and its metabolite, sirolimus, and evaluate associations of exposure parameters with safety and clinical activity. Exposure parameters were also correlated with pharmacogenomic responses in peripheral blood mononuclear cells (PBMCs).

[1]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[2]  D. Goldstein,et al.  Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. , 2003, The New England journal of medicine.

[3]  B. Geoerger,et al.  Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. , 2001, Cancer research.

[4]  M. Tyers,et al.  Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. , 2002, Cancer research.

[5]  P. Vogt.  PI 3-kinase, mTOR, protein synthesis and cancer. , 2001, Trends in molecular medicine.

[6]  D. DuBois,et al.  A formula to estimate the approximate surface area if height and weight be known , 1989 .

[7]  K. Nakayama,et al.  Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. , 2003, Biochemical pharmacology.

[8]  P. Frost,et al.  mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. , 2001, Endocrine-related cancer.

[9]  P. Hedrick,et al.  Gametic disequilibrium measures: proceed with caution. , 1987, Genetics.

[10]  E. Schuetz,et al.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.

[11]  F. Valentine,et al.  Population Pharmacokinetic Analysis of Didanosine (2′,3′‐Dideoxyinosine) Plasma Concentrations Obtained in Phase I Clinical Trials in Patients with AIDS or AIDS‐Related Complex , 1992, Journal of clinical pharmacology.

[12]  Manuel Hidalgo,et al.  Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. , 2003, Cancer research.

[13]  M. Relling,et al.  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. , 1998, The New England journal of medicine.

[14]  S. Krawetz,et al.  Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible tissues through the analysis of accessible tissues and cells. , 2004, Toxicology and applied pharmacology.

[15]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[17]  U. Christians,et al.  Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. , 1998, The Journal of pharmacology and experimental therapeutics.

[18]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[19]  B. Holman,et al.  In vivo metabolism of the technetium isonitrile complex [Tc(2-ethoxy-2-methyl-1-isocyanopropane)6]+. , 1994, Nuclear medicine and biology.

[20]  T. Fojo,et al.  Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Christopher J. Palestro,et al.  Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  W. Haefeli,et al.  Inhibition of P-Glycoprotein by Newer Antidepressants , 2003, Journal of Pharmacology and Experimental Therapeutics.

[23]  U. Christians,et al.  Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[24]  U. Hofmann,et al.  MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. , 2002, British journal of clinical pharmacology.

[25]  J. Kronauge,et al.  Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. , 1990, Circulation.

[26]  D. Lockhart,et al.  Expression monitoring by hybridization to high-density oligonucleotide arrays , 1996, Nature Biotechnology.

[27]  M. Fromm.  The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. , 2002, Advanced drug delivery reviews.

[28]  U. Brinkmann,et al.  The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels , 2001, The Pharmacogenomics Journal.

[29]  J. Bergh,et al.  Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial , 2000, The Lancet.

[30]  B. Swanson.  Delivery of High-Quality Biomarker Assays , 2002, Disease markers.

[31]  E. Franssen,et al.  Visualization of multidrug resistance in vivo , 1999, European Journal of Nuclear Medicine.

[32]  H. McLeod,et al.  MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. , 2001, Pharmacogenetics.

[33]  R. Kim,et al.  Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects , 2003, Clinical pharmacology and therapeutics.

[34]  K Püschel,et al.  Standard liver volume in the Caucasian population. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[35]  S. Kawasaki,et al.  Calculation of child and adult standard liver volume for liver transplantation , 1995, Hepatology.

[36]  E. Sausville,et al.  Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  J. Dobkin,et al.  Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  C. Clarke,et al.  CYP3A5 Genotype and Midazolam Clearance in Australian Patients Receiving Chemotherapy , 2004, Clinical pharmacology and therapeutics.

[39]  S. Uemoto,et al.  C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. , 2002, Pharmacogenetics.

[40]  B. Goh,et al.  Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Kasuga,et al.  Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects , 2002, Clinical pharmacology and therapeutics.

[42]  D. Slonim,et al.  Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls , 2001, Genome Biology.

[43]  H. Kroemer,et al.  Effect of levothyroxine administration on intestinal P‐glycoprotein expression: Consequences for drug disposition * , 2002, Clinical pharmacology and therapeutics.

[44]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[45]  E. de Vries,et al.  Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. , 1998, European journal of biochemistry.

[46]  H. Gurney,et al.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Sloane,et al.  An Introduction to Categorical Data Analysis , 1996 .

[48]  E. Schuetz,et al.  Interaction of Cytochrome P450 3A Inhibitors with P-Glycoprotein , 2002, Journal of Pharmacology and Experimental Therapeutics.

[49]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[50]  E. Ette,et al.  Stability and Performance of a Population Pharmacokinetic Model , 1997, Journal of clinical pharmacology.

[51]  C. Punt,et al.  Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  M. Matarrese,et al.  Biodistribution of Tc-99m methoxy-isobutyl-isonitrile (MIBI) in humans , 2004, European Journal of Nuclear Medicine.

[53]  R. Bookstein,et al.  Mutations to CCI-779 PTEN Enhanced Sensitivity of Multiple Myeloma Cells Containing Updated Version , 2002 .

[54]  E. B. Cunningham.  An inositolphosphate-binding immunophilin, IPBP12. , 1999, Blood.

[55]  M. Kasuga,et al.  Interaction of Docetaxel (“Taxotere”) with Human P‐Glycoprotein , 1999, Japanese journal of cancer research : Gann.

[56]  N H Holford,et al.  A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. , 1999, Computer methods and programs in biomedicine.

[57]  Emanuel F. Petricoin,et al.  Medical applications of microarray technologies: a regulatory science perspective , 2002, Nature Genetics.

[58]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Gorski,et al.  Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. , 2002, Drug metabolism and disposition: the biological fate of chemicals.